Cladribine
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Cladribine
- Pharmacist Assessment Report
- Cladribine: purine nucleoside analogue → parameningeal embryonal rhabdomyosarcoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cladribine: purine nucleoside analogue → parameningeal embryonal rhabdomyosarcoma
One-Sentence Summary
Cladribine is a purine nucleoside analogue that is marketed in Australia as an oral tablet. The TxGNN model predicts it may be relevant to parameningeal embryonal rhabdomyosarcoma, with a score of 0.9977. However, no clinical trials and no publications directly support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | parameningeal embryonal rhabdomyosarcoma |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, cladribine is a purine nucleoside analogue that resists breakdown by adenosine deaminase and is cytotoxic to lymphocytes and monocytes. Its activity depends on activation by deoxycytidine kinase (dCK).
The link to parameningeal embryonal rhabdomyosarcoma is weak. This is a solid tumour of muscle-lineage origin, and solid tumours of this type are generally not reported to be sensitive to cladribine. No mechanism specific to this disease has been established.
The score is also not independent evidence. Several closely related rhabdomyosarcoma subtypes and the parent term received near-identical scores in the same range, which suggests one shared model signal rather than separate lines of support. A sensible first research step would be laboratory testing of dCK-dependent sensitivity in rhabdomyosarcoma cell lines.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for this disease.
Australia Market Information
| ARTG Number | Product Name | Dosage Form |
|---|---|---|
| ARTG 11603Q | Mavenclad | Tablet 10 mg |
The approved indication text is not recorded in the local data.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analogue) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Full blood count with differential, liver and renal function |
| Handling Protection | Follow cytotoxic drug handling requirements |
Safety Considerations
- Drug Interactions: The data compiled for this report list 100 recorded interactions. Those shown are mostly rated Major, including:
- Corticosteroids: hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone
- Radiopharmaceuticals and radioimmunotherapy: ibritumomab tiuxetan, tositumomab, iobenguane (I-131), samarium (153Sm) lexidronam, strontium chloride Sr-89
- Deferiprone
Moderate interactions include palifermin, dipyridamole, cilostazol and eltrombopag.
Warnings and contraindications from the label are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. No clinical trial or publication studies cladribine in parameningeal embryonal rhabdomyosarcoma, and no disease-specific mechanism is established, so the evidence level is L5.
To proceed, the following is needed:
- Preclinical data showing cladribine sensitivity in rhabdomyosarcoma models, including dCK expression and activity
- Mechanism of action data
- Label warnings and contraindications from the TGA Product Information
- A specific safety and myelosuppression review, given the cytotoxic nature of the drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.